Paul, Company Secretary and Patient Advocate, was just 18 when he had his first melanoma biopsy. Since then, he’s had over 30 moles surgically removed from his body.
“When I was first diagnosed with stage II melanoma, there was a prevailing attitude of ‘better safe than sorry’. This meant any suspicious mole was removed, along with large amounts of surrounding tissue if it was confirmed to be malignant,” Paul said.
The many scars on Paul’s body are a reminder of this approach, which has become more nuanced over recent years, thanks to clinical trials such as the IMAGE and MelMarT trials.
“We’re truly entering an exciting age for melanoma and skin cancer research, and I’m so fortunate to see the latest advances through my work with MASC Trials.”
“As a MASC Trials patient advocate, I feel it’s critical for our trial outcomes and governance to be optimised with the patient experience in mind,” he said.